Modern cancer treatments (IO) have not addressed the cardiotoxicity problems of old chemotherapeutics.
Zantrene has been demonstrated to be cardioprotective preclinically and anecdotally in the the clinic against chemotherapeutics. Zantrene's cardioprotective MOA is unknown (or at least undisclosed). If the MOA is discovered to prevent T cells attacking a-myosin (this paper is saying modern IO treatments elicit this response) then there would be a rather large market opportunity for Zantrene to be used in combination with IO to prevent cardiotoxicity.
General Comments / Chat, page-6402
-
- There are more pages in this discussion • 5,482 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.000(0.00%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.62 | $1.57 | $180.6K | 113.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 145 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 23400 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |